ABIONYX Pharma SA reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 2.13 million compared to EUR 2.63 million a year ago. Net loss was EUR 2.25 million compared to EUR 2.55 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.02 EUR | -2.67% | -2.86% | -20.81% |
03-14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
03-11 | Abionyx: reduced net loss in 2023 | CF |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.81% | 36.27M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- ABNX Stock
- News ABIONYX Pharma
- ABIONYX Pharma SA Reports Earnings Results for the Half Year Ended June 30, 2023